T1	Value 9 19	= 18 years
T2	Person 23 26	age
R1	Has_value Arg1:T2 Arg2:T1	
T3	Non-query-able 28 153	Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
T4	Condition 180 182	UC
T5	Qualifier 187 205	moderate-to-severe
T6	Measurement 237 247	Mayo score
T7	Value 251 255	6-12
T8	Measurement 265 284	endoscopic subscore
T9	Value 285 287	=2
R2	Has_value Arg1:T6 Arg2:T7	
R3	AND Arg1:T6 Arg2:T8	
R4	Has_value Arg1:T8 Arg2:T9	
R5	Subsumes Arg1:T5 Arg2:T6	
R6	Has_qualifier Arg1:T4 Arg2:T5	
T10	Condition 306 325	inadequate response
T11	Condition 337 355	failed to tolerate
*	OR T10 T11
T12	Multiplier 357 366	1 or more
T13	Drug 408 431	oral 5-aminosalicylates
T14	Drug 433 453	oral corticosteroids
T15	Drug 455 473	azathioprine (AZA)
T16	Drug 482 504	6-mercaptopurine (6MP)
*	OR T15 T16 T14 T13
T17	Drug 509 523	corticosteroid
T18	Condition 524 533	dependent
R7	AND Arg1:T18 Arg2:T17	
T19	Non-representable 534 611	(ie, an inability to taper corticosteroids without recurrence of UC symptoms)
T20	Scope 408 504	oral 5-aminosalicylates, oral corticosteroids, azathioprine (AZA), and/or 6-mercaptopurine (6MP)
R8	Has_multiplier Arg1:T20 Arg2:T12	
T21	Scope 306 355	inadequate response to, or had failed to tolerate
R9	Has_scope Arg1:T21 Arg2:T20	
*	OR T21 T18
T22	Drug 649 672	oral 5-aminosalicylates
T24	Drug 676 691	corticosteroids
T25	Qualifier 710 721	stable dose
T26	Temporal 722 758	for at least 2 weeks before baseline
R10	Has_temporal Arg1:T25 Arg2:T26	
*	OR T22 T24
T27	Scope 649 691	oral 5-aminosalicylates or corticosteroids
T28	Drug 783 786	AZA
T29	Drug 794 797	6MP
*	OR T28 T29
T23	Qualifier 816 827	stable dose
T30	Temporal 828 864	for at least 4 weeks before baseline
R11	Has_temporal Arg1:T23 Arg2:T30	
T31	Scope 783 797	AZA and/or 6MP
R12	Has_qualifier Arg1:T31 Arg2:T23	
T32	Procedure 636 643	treated
R13	Has_qualifier Arg1:T27 Arg2:T25	
*	OR T31 T27
T33	Scope 649 864	oral 5-aminosalicylates or corticosteroids were to receive a stable dose for at least 2 weeks before baseline, and patients receiving AZA and/or 6MP were to receive a stable dose for at least 4 weeks before baseline
R14	Has_scope Arg1:T32 Arg2:T33	
T34	Non-representable 866 967	Patients were required to maintain stable doses of their concomitant UC medications during the study.
T35	Pregnancy_considerations 969 1140	Female subjects of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 6 months thereafter OR
T36	Pregnancy_considerations 1142 1272	Surgical sterilized female patients with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy OR
T37	Pregnancy_considerations 1274 1385	Postmenopausal women with postmenopausal defined as permanent cessation >1 year of previously occurring menses.
T38	Pregnancy_considerations 1387 1532	Female subjects' serum pregnancy test performed at the screening visit and urine pregnancy test performed at the baseline visit must be negative.
T39	Non-representable 1534 1607	Subjects have following investigations within 1 month prior to enrolment.
T40	Procedure 1609 1623	Routine bloods
T41	Procedure 1634 1637	U&E
T42	Procedure 1639 1642	FBC
T43	Procedure 1644 1648	LFTs
T44	Procedure 1650 1676	inflammatory markers (CRP)
T45	Procedure 1681 1688	albumin
*	OR T45 T44 T43 T42 T41
T46	Scope 1634 1688	U&E, FBC, LFTs, inflammatory markers (CRP) and albumin
R15	Subsumes Arg1:T40 Arg2:T46	
T47	Non-representable 1708 1748	Medical history, concomitant medications
T48	Procedure 1750 1800	Intradermal reaction to Tuberculin (PPD skin test)
T49	Procedure 1804 1884	Mycobacterium tuberculosis antigenspecific interferon-gamma release assay (IGRA)
*	OR T49 T48
T50	Temporal 1573 1606	within 1 month prior to enrolment
T51	Procedure 1900 1911	chest X-Ray
T52	Procedure 1886 1898	TB screening
R16	Subsumes Arg1:T52 Arg2:T51	
T53	Procedure 1951 1968	Stool examination
T54	Qualifier 1969 2022	for enteric pathogens including Clostridium difficile
R17	Has_qualifier Arg1:T53 Arg2:T54	
T55	Non-query-able 2054 2070	Informed consent
T56	Non-representable 2024 2052	Inclusion/exclusion criteria
T57	Procedure 2072 2082	Mayo score
T58	Procedure 2094 2107	sigmoidoscopy
R18	Subsumes Arg1:T57 Arg2:T58	
T59	Procedure 2180 2203	abdominal circumference
T60	Procedure 2169 2175	height
T61	Procedure 2158 2164	weight
